EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
|
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Results / Quarter/Forecast / Full year Ad-hoc notification in accordance with Sec. 17 of the MAR Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year Lübeck, April 16, 2026 – Following a decline in the same period of the prior year, Dräger’s net sales rose by 6.9 percent (net of currency effects; nominal: 3.5 percent) in the first quarter of 2026, based on preliminary calculations. At around EUR 766 million, they were around EUR 26 million above the prior-year figure (3 months 2025: EUR 730.3 million). Both divisions were able to grow again: the medical division posted an increase of 5.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 418 million (3 months 2025: EUR 413.1 million), while the safety division recorded an increase of 8.8 percent (net of currency effects; nominal: 6.6 percent) to around EUR 338 million (3 months 2025: EUR 317.2 million). Earnings before interest and taxes (EBIT) increased significantly to around EUR 18 million (3 months 2025: EUR 0.4 million). The EBIT margin rose to around 2.4 percent (3 months 2025: 0.1 percent). The main reason for this was the positive net sales development as well as the improvement in the gross margin to around 46.3 percent (3 months 2025: 45.8 percent). In addition, functional expenses fell by around EUR 2.7 million to around EUR 331 million (3 months 2025: EUR 333.7 million), partly as a result of a one-off payment for employees in Germany due to collective wage agreements in the prior year. Order intake increased by 3.4 percent (net of currency effects; nominal: 0.5 percent) to around EUR 865 million (3 months 2025: EUR 860.8 million). Both divisions were able to contribute to growth: In the medical division, order intake rose by 5.2 percent (net of currency effects; nominal: 1.3 percent) to around EUR 480 million (3 months 2025: EUR 473.7 million), while in the safety division it increased by 1.2 percent (net of currency effects; nominal: -0.6 percent) to around EUR 385 million (3 months 2025: EUR 387.1 million). Forecast for 2026 The full results for the first three months of the fiscal year will be published on April 30, 2026.
Drägerwerk AG & Co. KGaA
Investor Relations:
Disclaimer End of Inside Information Changed circumstances / true information: Ad-hoc notification in accordance with Sec. 17 of the MAR Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year Lübeck, April 16, 2026 – Following a decline in the same period of the prior year, Dräger’s net sales rose by 6.9 percent (net of currency effects; nominal: 3.5 percent) in the first quarter of 2026, based on preliminary calculations. At around EUR 756 million, they were around EUR 26 million above the prior-year figure (3 months 2025: EUR 730.3 million). Both divisions were able to grow again: the medical division posted an increase of 5.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 418 million (3 months 2025: EUR 413.1 million), while the safety division recorded an increase of 8.8 percent (net of currency effects; nominal: 6.6 percent) to around EUR 338 million (3 months 2025: EUR 317.2 million). Earnings before interest and taxes (EBIT) increased significantly to around EUR 18 million (3 months 2025: EUR 0.4 million). The EBIT margin rose to around 2.4 percent (3 months 2025: 0.1 percent). The main reason for this was the positive net sales development as well as the improvement in the gross margin to around 46.3 percent (3 months 2025: 45.8 percent). In addition, functional expenses fell by around EUR 2.7 million to around EUR 331 million (3 months 2025: EUR 333.7 million), partly as a result of a one-off payment for employees in Germany due to collective wage agreements in the prior year. Order intake increased by 3.4 percent (net of currency effects; nominal: 0.5 percent) to around EUR 865 million (3 months 2025: EUR 860.8 million). Both divisions were able to contribute to growth: In the medical division, order intake rose by 5.2 percent (net of currency effects; nominal: 1.3 percent) to around EUR 480 million (3 months 2025: EUR 473.7 million), while in the safety division it increased by 1.2 percent (net of currency effects; nominal: -0.6 percent) to around EUR 385 million (3 months 2025: EUR 387.1 million). Forecast for 2026 The full results for the first three months of the fiscal year will be published on April 30, 2026.
Drägerwerk AG & Co. KGaA
Investor Relations:
Disclaimer
16-Apr-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Drägerwerk AG & Co. KGaA |
| Moislinger Allee 53-55 | |
| 23558 Lübeck | |
| Germany | |
| Phone: | +49 (0)451 882-0 |
| Fax: | +49 (0)451 882-2080 |
| E-mail: | info@draeger.com |
| Internet: | www.draeger.com |
| ISIN: | DE0005550602, DE0005550636 (Vorzugsaktien) |
| WKN: | 555060, 555063 (Vorzugsaktien) |
| Indices: | SDAX, TecDax |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart, Tradegate BSX |
| EQS News ID: | 2310104 |
| End of Announcement | EQS News Service |
|
|
2310104 16-Apr-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 3.406,78 | 3.328,42 | 3.045,23 | 3.375,50 | 3.370,88 | 3.481,90 | 3.615,00 | |
| EBITDA1,2 | 521,07 | 421,00 | 55,80 | 315,00 | 339,90 | 377,60 | 385,00 | |
| EBITDA-Margin3 | 15,30 | 12,65 | 1,83 | 9,33 | 10,08 | 10,85 | 10,65 | |
| EBIT1,4 | 396,60 | 271,68 | -88,61 | 166,43 | 194,02 | 233,37 | 239,00 | |
| EBIT-Margin5 | 11,64 | 8,16 | -2,91 | 4,93 | 5,76 | 6,70 | 6,61 | |
| Net Profit (Loss)1 | 249,89 | 154,27 | -63,64 | 111,99 | 124,76 | 140,36 | 145,00 | |
| Net-Margin6 | 7,34 | 4,64 | -2,09 | 3,32 | 3,70 | 4,03 | 4,01 | |
| Cashflow1,7 | 459,98 | 384,89 | -144,23 | 189,68 | 167,31 | 238,33 | 200,00 | |
| Earnings per share8 | 10,19 | 7,13 | -3,41 | 5,86 | 6,67 | 7,42 | 8,90 | |
| Dividend per share8 | 0,13 | 0,13 | 0,13 | 1,74 | 1,97 | 2,21 | 2,21 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: -
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Drägerwerk ST | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 555060 | DE0005550602 | AG & Co. KGaA | 1.587,29 Mio € | 21.06.2010 | Kaufen | 9F5GVM4C+V2 |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 8,13 | 12,87 | 0,63 | 15,42 | 0,89 | 5,89 | 0,46 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,74 | 1,97 | 2,21 | 2,95% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 08.05.2026 | 30.04.2026 | 30.07.2026 | 29.10.2026 | 24.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +4,66% | +21,00% | +32,62% | +53,91% | +0,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
